Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

117 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cognitive Composites Domain Scores Related to Neuroimaging Biomarkers within Probable-Amnestic Mild Cognitive Impairment-Storage Subtype.
Espinosa A, Alegret M, Pesini P, Valero S, Lafuente A, Buendía M, San José I, Ibarria M, Tejero MA, Giménez J, Ruiz S, Hernández I, Pujadas F, Martínez-Lage P, Munuera J, Arbizu J, Tárraga L, Hendrix SB, Ruiz A, Becker JT, Landau SM, Sotolongo-Grau O, Sarasa M, Boada M; AB255 Study Group; Alzheimer’s Disease Neuroimaging Initiative. Espinosa A, et al. Among authors: arbizu j. J Alzheimers Dis. 2017;57(2):447-459. doi: 10.3233/JAD-161223. J Alzheimers Dis. 2017. PMID: 28269787 Free PMC article.
Plasma Aβ42/40 ratio alone or combined with FDG-PET can accurately predict amyloid-PET positivity: a cross-sectional analysis from the AB255 Study.
Pérez-Grijalba V, Arbizu J, Romero J, Prieto E, Pesini P, Sarasa L, Guillen F, Monleón I, San-José I, Martínez-Lage P, Munuera J, Hernández I, Buendía M, Sotolongo-Grau O, Alegret M, Ruiz A, Tárraga L, Boada M, Sarasa M; AB255 Study Group. Pérez-Grijalba V, et al. Among authors: arbizu j. Alzheimers Res Ther. 2019 Dec 1;11(1):96. doi: 10.1186/s13195-019-0549-1. Alzheimers Res Ther. 2019. PMID: 31787105 Free PMC article.
Automated analysis of FDG PET as a tool for single-subject probabilistic prediction and detection of Alzheimer's disease dementia.
Arbizu J, Prieto E, Martínez-Lage P, Martí-Climent JM, García-Granero M, Lamet I, Pastor P, Riverol M, Gómez-Isla MT, Peñuelas I, Richter JA, Weiner MW; Alzheimer's Disease Neuroimaging Initiative. Arbizu J, et al. Eur J Nucl Med Mol Imaging. 2013 Sep;40(9):1394-405. doi: 10.1007/s00259-013-2458-z. Epub 2013 May 29. Eur J Nucl Med Mol Imaging. 2013. PMID: 23715905
Decreased carbon-11-flumazenil binding in early Alzheimer's disease.
Pascual B, Prieto E, Arbizu J, Marti-Climent JM, Peñuelas I, Quincoces G, Zarauza R, Pappatà S, Masdeu JC. Pascual B, et al. Among authors: arbizu j. Brain. 2012 Sep;135(Pt 9):2817-25. doi: 10.1093/brain/aws210. Brain. 2012. PMID: 22961552
Diagnostic utility of 18F-Fluorodeoxyglucose positron emission tomography (FDG-PET) in asymptomatic subjects at increased risk for Alzheimer's disease.
Drzezga A, Altomare D, Festari C, Arbizu J, Orini S, Herholz K, Nestor P, Agosta F, Bouwman F, Nobili F, Walker Z, Frisoni GB, Boccardi M; EANM-EAN Task Force for the Prescription of FDG-PET for Dementing Neurodegenerative Disorders. Drzezga A, et al. Among authors: arbizu j. Eur J Nucl Med Mol Imaging. 2018 Jul;45(9):1487-1496. doi: 10.1007/s00259-018-4032-1. Epub 2018 May 13. Eur J Nucl Med Mol Imaging. 2018. PMID: 29756163 Review.
Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias.
Chételat G, Arbizu J, Barthel H, Garibotto V, Law I, Morbelli S, van de Giessen E, Agosta F, Barkhof F, Brooks DJ, Carrillo MC, Dubois B, Fjell AM, Frisoni GB, Hansson O, Herholz K, Hutton BF, Jack CR Jr, Lammertsma AA, Landau SM, Minoshima S, Nobili F, Nordberg A, Ossenkoppele R, Oyen WJG, Perani D, Rabinovici GD, Scheltens P, Villemagne VL, Zetterberg H, Drzezga A. Chételat G, et al. Among authors: arbizu j. Lancet Neurol. 2020 Nov;19(11):951-962. doi: 10.1016/S1474-4422(20)30314-8. Lancet Neurol. 2020. PMID: 33098804 Review.
117 results